Cardiovascular
Thrombolysis
0
Pipeline Programs↗
4
Active Trials↗
1
Companies Involved↗
Thrombolysis is an early-stage landscape with 0 programs across 1 company. The most active players are ImaRx Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
15
clinical trials
Completed9 · 60%
Recruiting3 · 20%
Active, not recruiting1 · 7%
Withdrawn1 · 7%
Terminated1 · 7%
Clinical Trials
Trial Activity
15 trials
Intravenous Thrombolysis and NOAC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06749834·280 enrolled
Thrombolysis in Factor Xa-inhibitors Trial
Recruiting·—·Phase 3·NCT06878066·300 enrolled
Sonothrombolysis in Patients With STEMI
Completed·—·Phase 2·NCT03092089·15 enrolled
Extending the Time for Thrombolysis in Emergency Neurological Deficits
Completed·—·Phase 3·NCT00887328·180 enrolled
A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Completed·—·Phase 2·NCT01282242·88 enrolled
EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)
Completed·—·Phase 3·NCT01580839·45 enrolled
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Withdrawn·—·Phase 4·NCT02048085
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)